{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-138467","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.653164+00:00","generated_at":"2026-05-29T01:36:05.873976+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"First patient dosed in Ultragenyx Phase 3 Aspire study of GTX-102 for Angelman syndrome","bullets":["Global Phase 3 Aspire study will enroll ~120 children ages 4-17 with full maternal UBE3A deletion.","Patients randomized 1:1 to GTX-102 intrathecal injections or sham comparator for 48-week primary analysis.","Primary endpoint: cognition improvement (Bayley-4 cognitive raw score); key secondary: Multi-domain Responder Index.","Active group receives three monthly 8 mg loading doses then quarterly maintenance up to 14 mg; sham crossover after Week 48."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-138467","json":"https://secwatch.observer/filing/0000950170-24-138467.json","markdown":"https://secwatch.observer/filing/0000950170-24-138467.md","text":"https://secwatch.observer/filing/0000950170-24-138467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024138467/0000950170-24-138467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024138467/rare-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:36:05.873976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}